Loading...
•
Jun 30, 2020
Surmodics Q3 2020 Earnings Report
Reported revenue increase of 10% year-over-year and GAAP EPS of $0.18.
Key Takeaways
Surmodics reported a revenue increase of 10% year-over-year, with GAAP EPS at $0.18 and non-GAAP EPS at $0.21. The company achieved critical milestones with CE Mark for SurVeil DCB and FDA clearance for Sublime PTA balloon catheter.
Revenue increased by 10% year-over-year.
GAAP EPS was $0.18, and non-GAAP EPS was $0.21.
CE Mark was received for SurVeil drug coated balloon (DCB).
FDA clearance was received for Sublime radial-access 0.014” PTA balloon catheter.
Revenue by Segment
Forward Guidance
Due to the continued uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, the Company will not provide financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...